Question-and-Answer SessionMichael SchmidtGuggenheim Securities, LLC, Research Division So we'll jump right into Q&A. So obviously, an exciting time for the company with pivotal studies underway for daraxonrasib, more to come. And so just jumping right into a question. Your most advanced registration study is the second-line pancreatic cancer trial, RASolute 302, that's ongoing and nearing completion of enrollment. And yes, as we look forward to the first registration data disclosure next year. The Phase I ...